Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...
The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic ...
Metabolic-dysfunction-associated steatotic liver disease (MASLD) arises from excessive intrahepatic triglyceride accumulation ...
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...
THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.
A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...
Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...
FASCINIT in patients with suspected or confirmed diagnosis of MASLD/MASH: The trial is expected to evaluate the safety and efficacy of denifanstat in this population, with the primary endpoint of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results